Journal Specialty Index
Endocrinology, Diabetes & Metabolism
Topic | Issue |
Prevention and Updated Management for Diabetic Kidney Disease | AUGUST 2024 ‧ VOL. 16 ‧ NO. 8 |
Stratification of the Thyroid Nodule With Ultrasound Examination | AUGUST 2024 ‧ VOL. 16 ‧ NO. 8 |
Understanding the Diagnosis of Polycystic Ovarian Syndrome | AUGUST 2024 ‧ VOL. 16 ‧ NO. 8 |
Recent Advances in Nuclear Imaging with Improved Diagnostic Accuracy for Common Endocrine Disorders | AUGUST 2024 ‧ VOL. 16 ‧ NO. 8 |
Incretin-Based Therapy in Obesity | JANUARY 2024 ‧ VOL. 16 ‧ NO. 1 |
Lowered BMI Criteria for Metabolic Bariatric Surgery | JANUARY 2024 ‧ VOL. 16 ‧ NO. 1 |
Renal Health and Obesity | JANUARY 2024 ‧ VOL. 16 ‧ NO. 1 |
Update in the Management of Fatty Liver | JANUARY 2024 ‧ VOL. 16 ‧ NO. 1 |
Diabetes in Pregnancy | JULY 2023 ‧ VOL. 15 ‧ NO. 5 |
Using Neuro-Linguistic Programming Techniques to Facilitate Dietary Habits Change | JULY 2023 ‧ VOL. 15 ‧ NO. 5 |
Evolution of Management of Papillary Thyroid Microcarcinoma: From Resection to No Resection and Partial Resection | JULY 2023 ‧ VOL. 15 ‧ NO. 5 |
Cardiometabolic Risks of the Sugar Substitute Erythritol | JULY 2023 ‧ VOL. 15 ‧ NO. 5 |
SGLT2 Inhibitors: Latest Update | JULY 2023 ‧ VOL. 15 ‧ NO. 5 |
Diabetes and Cardiology - A Concise and Comprehensive 2022 Update for Frontline Family Doctors | JULY 2022 ‧ VOL. 14 ‧ NO. 6 |
Update on Glucagon-like Peptide 1 Receptor Agonists | JULY 2022 ‧ VOL. 14 ‧ NO. 6 |
Thyrotoxicosis Diagnosis/Treatment FAQs | JULY 2022 ‧ VOL. 14 ‧ NO. 6 |
Management of Adrenal Incidentaloma: Initial Workup and Follow Up | JULY 2022 ‧ VOL. 14 ‧ NO. 6 |
Practical Guidance From EAS for Combination Lipid-Modifying Therapy in High-and Very-High-Risk Patients | MAY 2022 ‧ VOL. 14 ‧ NO. 4 |
Advances in LDL-C Management: What's Next? | MAY 2022 ‧ VOL. 14 ‧ NO. 4 |
Update on Obesity Medications in 2021/2022 | JANUARY 2022 ‧ VOL. 14 ‧ NO. 1 |
New Challenges for Patients Undergoing Bariatric Surgery in the Time of COVID-19 | JANUARY 2022 ‧ VOL. 14 ‧ NO. 1 |
How to Maintain Exercise Levels During the COVID-19 Pandemic | JANUARY 2022 ‧ VOL. 14 ‧ NO. 1 |
Review of Antihyperglycaemic Agents and Updates for 2021 | APRIL 2021 ‧ VOL. 13 ‧ NO. 4 |
Primary Hyperparathyroidism - An Overlooked Disease | APRIL 2021 ‧ VOL. 13 ‧ NO. 4 |
Oral Contraceptives, Hormone Replacement Therapy and Breast Cancer Risk | APRIL 2021 ‧ VOL. 13 ‧ NO. 4 |
Metabolic Diseases in People Living With HIV | DECEMBER 2020 ‧ VOL. 12 ‧ NO. 10 |
Obesity and Dyslipidaemia | AUGUST 2020 ‧ VOL. 12 ‧ NO. 7 |
COVID-19 & Obesity - At the Intersection of a Pandemic and an Epidemic | AUGUST 2020 ‧ VOL. 12 ‧ NO. 7 |
Kidney Disorders and Renoprotection in Obese Patients | AUGUST 2020 ‧ VOL. 12 ‧ NO. 7 |
Combating Obesity Through Physical Activity | AUGUST 2020 ‧ VOL. 12 ‧ NO. 7 |
Recent Advances in Diabetes Technology: Continuous Glucose Monitoring Systems | APRIL 2020 ‧ VOL. 12 ‧ NO. 4 |
Diabetes Foot Disease and Management | APRIL 2020 ‧ VOL. 12 ‧ NO. 4 |
Current Evidence on the Role of Surgery in the Management of Graves' Disease | APRIL 2020 ‧ VOL. 12 ‧ NO. 4 |
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure | APRIL 2020 ‧ VOL. 12 ‧ NO. 4 |
Diabetes Breakthrough Treatment for Cardiovascular Diseases and Beyond | FEBRUARY 2020 ‧ VOL. 12 ‧ NO. 2 |
The Story of Statins | NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8 |
Treatment of Non-alcoholic Fatty Liver Disease: Present and Future | OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7 |
More Sweat, Less Sweet: How an Exercise Programme Made Positive Changes for an Obese Patient with Type 2 Diabetes | OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7 |
Management of Type 2 Diabetes Mellitus in Obese Patients | OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7 |
Update on Medical Treatment of Obesity | OCTOBER 2019 ‧ VOL. 11 ‧ NO. 7 |
New Classes of Diabetes Mellitus Drugs: From Insulin to Non-insulin | JULY 2019 ‧ VOL. 11 ‧ NO. 5 |
Familial Hypercholesterolaemia - Finding the Needle in the Haystack | JULY 2019 ‧ VOL. 11 ‧ NO. 5 |
New Challenges in Endocrinology - Immunotherapy-Related Endocrinopathies | APRIL 2019 ‧ VOL. 11 ‧ NO. 3 |
Advances in Scarless Management of Benign Thyroid Nodule: From Ablation to Resection | APRIL 2019 ‧ VOL. 11 ‧ NO. 3 |
Diabetic Eye Diseases | APRIL 2019 ‧ VOL. 11 ‧ NO. 3 |
Updates on New Strategies and Pharmacological Weapons Against Type 2 Diabetes Mellitus | APRIL 2019 ‧ VOL. 11 ‧ NO. 3 |
Food Supplements and Cholesterol/Cardiovascular Health | NOVEMBER 2018 ‧ VOL. 10 ‧ NO. 7 |
Reducing LDL Cholesterol to Prevent Atherosclerotic Cardiovascular Disease | AUGUST 2018 ‧ VOL. 10 ‧ NO. 5 |
COPD with Comorbid Diabetes Mellitus | MAY 2018 ‧ VOL. 10 ‧ NO. 4 |
The More I Know, The More I Know That I Don't Know | APRIL 2018 ‧ VOL. 10 ‧ NO. 3 |
What's Next After Metformin? How to Choose the Second Anti-Diabetic Drug in a Primary Care Setting | APRIL 2018 ‧ VOL. 10 ‧ NO. 3 |
Advancements in Obesity Medicine in the Past Decade | APRIL 2018 ‧ VOL. 10 ‧ NO. 3 |
Screening and Management of Diabetic Nephropathy | APRIL 2018 ‧ VOL. 10 ‧ NO. 3 |
Coronary Artery Disease Screening in Patients with Type 2 Diabetes | APRIL 2018 ‧ VOL. 10 ‧ NO. 3 |
Metabolic Syndrome and Perspectives for Future Research: A Brief Review | JANUARY 2018 ‧ VOL. 10 ‧ NO. 1 |
Latest Insights on the Treatment of Dyslipidemia | NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7 |
Recent Advances in the Management of Type 2 Diabetes | NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7 |
Clinical Benefits of the Potent Antioxidant Probucol | NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7 |
Insulin Initiation in Patients with Type 2 Diabetes | JULY 2017 ‧ VOL. 9 ‧ NO. 5 |
Comorbidities of Gout | APRIL 2017 ‧ VOL. 9 ‧ NO. 3 |
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs | NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7 |
Oxidative Stress and Inflammation in Atherosclerosis | NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7 |
SGLT2 Inhibitors: A New Class of Antidiabetic Drugs | SEPTEMBER 2016 ‧ VOL. 8 ‧ NO. 6 |
Management of Obesity in Patients with Type 2 Diabetes | SEPTEMBER 2016 ‧ VOL. 8 ‧ NO. 6 |
The Important Role of Diet in the Management of Hypercholesterolemia and Prevention of Coronary Heart Disease | JULY 2016 ‧ VOL. 8 ‧ NO. 5 |
Gout: What is the Treatment Target and How to Achieve the Target? | FEBRUARY 2016 ‧ VOL. 8 ‧ NO. 2 |
Pharmacogenomics: The Promises of Personalized Medicine | JANUARY 2016 ‧ VOL. 8 ‧ NO. 1 |
The Impact of GLP-1 Receptor Agonists on Weight in Obese Patients with Type 2 Diabetes Mellitus | DECEMBER 2015 ‧ VOL. 7 ‧ NO. 7 |
Role of Probucol in the Current Treatment of Atherosclerosis and Vascular Disease | NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6 |
2015 Update in Diabetes, Endocrinology & Metabolism | NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6 |
Probucol: Reappraisal of an Old Drug for Atherosclerosis | MAY 2015 ‧ VOL. 7 ‧ NO. 3 |
Year of Endocrinology, Diabetes & Metabolism 2014 | NOVEMBER 2014 ‧ VOL. 6 ‧ NO. 6 |
Update on the Use of Angiotensin Receptor Blockers in Hypertension: A Focus on Azilsartan Medoxomil | JUNE 2014 ‧ VOL. 6 ‧ NO. 3 |
Update on Gout Management | DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7 |
Type 2 Diabetes and Comorbidities: The Management Challenges | DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7 |
Blood Pressure Variability: Is It Important and How Can We Assess It? | DECEMBER 2013 ‧ VOL. 5 ‧ NO. 7 |
Glucocorticoid-Induced Osteoporosis - Who Should be Treated | MAY 2013 ‧ VOL. 5 ‧ NO. 3 |
Heart Rate Reduction as a Goal in the Management of Cardiovascular Risk | MARCH 2013 ‧ VOL. 5 ‧ NO. 2 |
Role of Bone Mineral Density in Fracture Risk Assessment | MARCH 2013 ‧ VOL. 5 ‧ NO. 2 |
Update on Management of Gout and Hyperuricaemia | JANUARY 2013 ‧ VOL. 5 ‧ NO. 1 |
New Directions in Management Type 2 Diabetes Mellitus | DECEMBER 2012 ‧ VOL. 4 ‧ No. 7 |
The Role of Combination Therapy in the Management of Hypertension | MAY 2012 ‧ VOL. 4 ‧ NO. 3 |
Update in Oral Antidiabetic Drugs in Type 2 Diabetes | DECEMBER 2011 ‧ VOL. 3 ‧ NO. 7 |
Niacin for the Treatment of Dyslipidaemia and Atherosclerosis | JULY 2011 ‧ VOL. 3 ‧ NO. 4 |
Atypical Femoral Fractures and Bisphosphonates: New Aspects | MAY 2011 ‧ VOL. 3 ‧ NO. 3 |
New Treatment Modalities in Osteoporosis | MARCH 2011 ‧ VOL. 3 ‧ NO. 2 |
Recent Advances in Therapeutics in Osteoporosis | JANUARY 2011 ‧ VOL. 3 ‧ NO. 1 |
The Role of thiazolidinediones in the Management of Type 2 Diabetes | DECEMBER 2010 ‧ VOL. 2 ‧ NO. 8 |
Increase in Bone Mineral Density During Testosterone Therapy in Chinese Hypogonadal Men | MAY 2010 ‧ VOL. 2 ‧ NO. 3 |
Differential Diagnosis of Hypercalcaemia | APRIL 2009 ‧ VOL. 1 ‧ NO. 2 |